SlideShare a Scribd company logo
1 of 20
Download to read offline
The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
References/Data Source ,[object Object],[object Object],[object Object],[object Object]
Table of Contents ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Orphan Drug Act ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Provisions of the Orphan Drug Act: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Governmental Entities Implementing the Orphan Drug Act ,[object Object],[object Object],[object Object]
Has the Orphan Drug Act Met It’s Objectives? ,[object Object],[object Object],[object Object],[object Object]
Findings: ,[object Object],[object Object],[object Object],[object Object]
Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
Findings: ,[object Object],[object Object],[object Object],[object Object]
Conclusion: ,[object Object],[object Object],[object Object]
What Does This Mean To You?: Managed Care Vision Today & Beyond ,[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns (Abroad & Here) ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object]
Trends & Concerns: Abroad & Here ,[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Implications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Conclusions ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDr. Vishal Pawar
 
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSAshish Bajaj
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairsGirish Swami
 
Who art & med dra
Who art & med draWho art & med dra
Who art & med draPlessan Joy
 
Defined daily dose-DDD
Defined daily dose-DDDDefined daily dose-DDD
Defined daily dose-DDDMubasheeraMg
 
IND Application Process and Best Practices
IND Application Process and Best PracticesIND Application Process and Best Practices
IND Application Process and Best PracticesCFTCC
 
Designing of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedDesigning of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedRumana Hameed
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Saiyad Arsh zia
 
New drugs and Clinical Trials Rule in india 2019
New drugs and Clinical Trials Rule in india 2019New drugs and Clinical Trials Rule in india 2019
New drugs and Clinical Trials Rule in india 2019Arya V Devi
 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfRumana Hameed
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxINSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxRAHUL PAL
 
Pharmacovigilance Workshop: Case Studies
Pharmacovigilance Workshop: Case Studies Pharmacovigilance Workshop: Case Studies
Pharmacovigilance Workshop: Case Studies Arete-Zoe, LLC
 

What's hot (20)

Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.
 
Orphan drugs
Orphan drugsOrphan drugs
Orphan drugs
 
Drugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan DrugsDrugs for rare diseases, Orphan Drugs
Drugs for rare diseases, Orphan Drugs
 
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGSORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
ORPHAN DRUGS- ACTS, PAST AND CURRENT SCENARIO, WITH UPCOMING DRUGS
 
Regulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan pptRegulatory requirnment and approval procedure of drugs in japan ppt
Regulatory requirnment and approval procedure of drugs in japan ppt
 
CIOMS (1).pptx
CIOMS (1).pptxCIOMS (1).pptx
CIOMS (1).pptx
 
Anda
AndaAnda
Anda
 
Schedule y
Schedule ySchedule y
Schedule y
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
 
Who art & med dra
Who art & med draWho art & med dra
Who art & med dra
 
Defined daily dose-DDD
Defined daily dose-DDDDefined daily dose-DDD
Defined daily dose-DDD
 
IND Application Process and Best Practices
IND Application Process and Best PracticesIND Application Process and Best Practices
IND Application Process and Best Practices
 
Designing of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedDesigning of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameed
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Schedule y
Schedule  ySchedule  y
Schedule y
 
New drugs and Clinical Trials Rule in india 2019
New drugs and Clinical Trials Rule in india 2019New drugs and Clinical Trials Rule in india 2019
New drugs and Clinical Trials Rule in india 2019
 
An introduction to the EMA
An introduction to the EMAAn introduction to the EMA
An introduction to the EMA
 
Designing of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crfDesigning of clinical study documentation -protocol and crf
Designing of clinical study documentation -protocol and crf
 
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptxINSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
INSTITUTIONAL REVIEW BOARD (IRB/IEC).pptx
 
Pharmacovigilance Workshop: Case Studies
Pharmacovigilance Workshop: Case Studies Pharmacovigilance Workshop: Case Studies
Pharmacovigilance Workshop: Case Studies
 

Similar to The Orphan Drug Act

The science of hope
The science of hopeThe science of hope
The science of hopeFreedom Monk
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesKuldeep Badoniya
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Harsha Rajasimha
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.docsuprajakotam
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaCGI
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigmsjalisman
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010HealthlinkWorldwide
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environmentspmaugeri
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...Dr Aneek Gupta
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...MedicineAndHealthUSA
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneAmerica's Health Insurance Plans
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2bahlinnm
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPMauro Placchi
 

Similar to The Orphan Drug Act (20)

The science of hope
The science of hopeThe science of hope
The science of hope
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Ethical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research IncentivesEthical Implications of Orphan Drug Research Incentives
Ethical Implications of Orphan Drug Research Incentives
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
MMHA 6135 WK 5 App
MMHA 6135 WK 5 AppMMHA 6135 WK 5 App
MMHA 6135 WK 5 App
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
Rajasimha-ORDI-RareDiseasePolicy-ODA-Delhi-22Apr2016
 
orphan drugs writeup.doc
orphan drugs writeup.docorphan drugs writeup.doc
orphan drugs writeup.doc
 
Read Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharmaRead Logica’s paper on the need for convergence of healthcare and pharma
Read Logica’s paper on the need for convergence of healthcare and pharma
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
Lisman New Paradigms
Lisman New ParadigmsLisman New Paradigms
Lisman New Paradigms
 
Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010Health Exchange: Access to medicines April 2010
Health Exchange: Access to medicines April 2010
 
Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environments
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
Zweig powerpoint on Palliative Care in Nursing Homes for Theme Session co-spo...
 
The High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for EveryoneThe High Prices of Prescription Drugs Increase Costs for Everyone
The High Prices of Prescription Drugs Increase Costs for Everyone
 
Proper prescribing module1_revised v2
Proper prescribing module1_revised v2Proper prescribing module1_revised v2
Proper prescribing module1_revised v2
 
Demonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMPDemonstrating Significant Benefit for an OMP
Demonstrating Significant Benefit for an OMP
 

The Orphan Drug Act

  • 1. The Orphan Drug Act Jeff W. Bailey MS Senior Regional Business Manager Shire Human Genetic Therapies June 2009
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9. Findings: Total Orphan Designations and Approvals 68 79 67 55 60 56 58 65 56 80 89 75 73 59 33 48 41 1 D E S I G N A T E 14 20 20 19 23 11 11 13 13 12 12 12 11 9 6 7 3 2 A P P R O V A L S 00 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 Y E A R
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.